We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam Announces Grant of new Patent Covering RNAi Therapeutics in the United Kingdom
News

Alnylam Announces Grant of new Patent Covering RNAi Therapeutics in the United Kingdom

Alnylam Announces Grant of new Patent Covering RNAi Therapeutics in the United Kingdom
News

Alnylam Announces Grant of new Patent Covering RNAi Therapeutics in the United Kingdom

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Announces Grant of new Patent Covering RNAi Therapeutics in the United Kingdom"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alnylam Pharmaceuticals, Inc. announced that the United Kingdom Patent Office has granted a patent (UK 2417727 or “’727 patent”) for the Woppman et al. patent series, entitled “Double-stranded ribonucleic acid with increased effectiveness in an organism.”

The newly granted patent includes 32 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.

The claims cover siRNA molecules of any length that contain “overhang” and “blunt end” design features, including siRNAs containing chemical modifications and certain novel motifs.

“Our intellectual property estate for RNAi therapeutics continues to grow substantially as evidenced by this new patent grant, the first in a distinct patent series that describes important design features for RNAi therapeutics. With this progress, we are extending the scope of our comprehensive ‘first-mover’ consolidation of early filed RNAi fundamental patents and patent applications,” said Barry Greene, President and Chief Operating Officer of Alnylam.

“We expect that many additional patents owned or licensed exclusively to Alnylam will be awarded this year and in the years to come, broadening the sphere of our patent portfolio for siRNAs in markets across the world,” Greene added.

The claims for the ’727 patent cover compositions and methods for siRNAs, including, in general terms:

- a double-stranded RNA of any length having effectiveness in inhibiting a target gene by RNAi;

- with “overhang” and “blunt-end” design features and certain nucleotide pair motifs;

- with or without chemical modifications, with no limitations as to the number of such modifications;

- including pharmaceutical compositions of the claimed siRNAs for inhibiting the expression of a target gene by means of RNAi;

- and/or, methods for the selection of such an siRNA molecule or methods for inhibiting the expression of a target gene in a cell.

The claims of the Woppman et al. ’727 patent are provided on the company’s website, together with claims from other Alnylam owned or licensed patents.

Advertisement